Physician profile
Akash Kumar
NPI 1750708731
$135,939.03
in general payments reported to CMS, 2019-2025
10 companies · $67K in 2025
The $67K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.03 · 2021: $13.64 · 2022: $122 · 2023: $29K · 2024: $39K · 2025: $67K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $99K · Honoraria: $16K · Travel and Lodging: $9,493 · Consulting Fee: $7,555 · Food and Beverage: $3,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $99,125.50 |
| Honoraria | $15,892.50 |
| Travel and Lodging | $9,493.31 |
| Consulting Fee | $7,555.00 |
| Food and Beverage | $3,713.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $37,747.22 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $30,705.46 | 2023-2024 | Zeposia |
| Celltrion USA INC. | $25,677.08 | 2024-2025 | Zymfentra, Vegzelma |
| Lilly USA, LLC | $23,846.97 | 2025 | Omvoh |
| Janssen Biotech, INC. | $15,772.36 | 2025 | Tremfya, Stelara |
| Celgene Corporation | $1,399.58 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $628.65 | 2020-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.05 | 2022-2024 | Xifaxan |
| Abbvie INC. | $58.10 | 2024-2025 | |
| Pfizer INC. | $39.56 | 2023-2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akash Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.